558 related articles for article (PubMed ID: 25833810)
1. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.
Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K
Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810
[TBL] [Abstract][Full Text] [Related]
2. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
3. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation.
Zappulla JP; Dubreuil P; Desbois S; Létard S; Hamouda NB; Daëron M; Delsol G; Arock M; Liblau RS
J Exp Med; 2005 Dec; 202(12):1635-41. PubMed ID: 16352739
[TBL] [Abstract][Full Text] [Related]
4. Mastocytosis: from a Molecular Point of View.
Komi DEA; Rambasek T; Wöhrl S
Clin Rev Allergy Immunol; 2018 Jun; 54(3):397-411. PubMed ID: 28725969
[TBL] [Abstract][Full Text] [Related]
5. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
6. Mastocytosis cells bearing a c-kit activating point mutation are characterized by hypersensitivity to stem cell factor and increased apoptosis.
Dror Y; Leaker M; Caruana G; Bernstein A; Freedman MH
Br J Haematol; 2000 Mar; 108(4):729-36. PubMed ID: 10792276
[TBL] [Abstract][Full Text] [Related]
7. A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.
Smrž D; Bandara G; Zhang S; Mock BA; Beaven MA; Metcalfe DD; Gilfillan AM
J Immunol Methods; 2013 Apr; 390(1-2):52-62. PubMed ID: 23357051
[TBL] [Abstract][Full Text] [Related]
8. Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation.
Mizrahi K; Stein J; Pearl-Yafe M; Kaplan O; Yaniv I; Askenasy N
Leukemia; 2010 Jul; 24(7):1325-34. PubMed ID: 20485377
[TBL] [Abstract][Full Text] [Related]
9. RabGEF1 regulates stem cell factor/c-Kit-mediated signaling events and biological responses in mast cells.
Kalesnikoff J; Rios EJ; Chen CC; Nakae S; Zabel BA; Butcher EC; Tsai M; Tam SY; Galli SJ
Proc Natl Acad Sci U S A; 2006 Feb; 103(8):2659-64. PubMed ID: 16533754
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
11. Targeting c-kit in the therapy of mast cell disorders: current update.
El-Agamy DS
Eur J Pharmacol; 2012 Sep; 690(1-3):1-3. PubMed ID: 22789565
[TBL] [Abstract][Full Text] [Related]
12. Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis.
Wimazal F; Walchshofer S; Baghestanian M; Chott A; Sperr WR; Kopp C; Sillaber C; Semper H; Horny HP; Tröndle U; Födinger M; Schwarzinger I; Lechner K; Valent P
Wien Klin Wochenschr; 1998 Feb; 110(3):79-88. PubMed ID: 9553202
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
14. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors.
Pittoni P; Piconese S; Tripodo C; Colombo MP
Oncogene; 2011 Feb; 30(7):757-69. PubMed ID: 21057534
[TBL] [Abstract][Full Text] [Related]
15. Molecular defects in mastocytosis: KIT and beyond KIT.
Bibi S; Langenfeld F; Jeanningros S; Brenet F; Soucie E; Hermine O; Damaj G; Dubreuil P; Arock M
Immunol Allergy Clin North Am; 2014 May; 34(2):239-62. PubMed ID: 24745672
[TBL] [Abstract][Full Text] [Related]
16. Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro.
McManus S; Chamoux E; Bisson M; Roux S
Apoptosis; 2012 Feb; 17(2):121-31. PubMed ID: 21972115
[TBL] [Abstract][Full Text] [Related]
17. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
18. FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9.
Ito F; Toyota N; Sakai H; Takahashi H; Iizuka H
Arch Dermatol Res; 1999 May; 291(5):275-83. PubMed ID: 10367710
[TBL] [Abstract][Full Text] [Related]
19. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
Jin B; Ding K; Pan J
Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
[TBL] [Abstract][Full Text] [Related]
20. Stem cell factor augments Fc epsilon RI-mediated TNF-alpha production and stimulates MAP kinases via a different pathway in MC/9 mast cells.
Ishizuka T; Kawasome H; Terada N; Takeda K; Gerwins P; Keller GM; Johnson GL; Gelfand EW
J Immunol; 1998 Oct; 161(7):3624-30. PubMed ID: 9759885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
